A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Honghao Yang, Shahrooz Eshaghian(Cedars-Sinai Medical Center), Benjamin Eades(James Madison University), Stephanie R. Rice(Oncotherapeutics (United States)), Tahmineh Safaie(Oncotherapeutics (United States)), Susanna Kim(Oncotherapeutics (United States)), Matthew Brobeck(Oncotherapeutics (United States)), Ashley Del Dosso(University of Southern California), Sean Bujarski, Yohana Sebhat, Mehdi M. Moezi, Stephen Lim(Cedars-Sinai Medical Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Rudra Ray, Gary K. Schwartz(Baylor University Medical Center), Andrea Limon(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research)
Cited by 2
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725